Filing Details
- Accession Number:
- 0001415889-24-005883
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-29 16:26:39
- Reporting Period:
- 2024-02-27
- Accepted Time:
- 2024-02-29 16:26:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1730430 | Kiniksa Pharmaceuticals Ltd. | KNSA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1741533 | F. John Paolini | C/O Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton D0 HM 11 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Share | Acquisiton | 2024-02-27 | 10,156 | $1.86 | 55,048 | No | 4 | M | Direct | |
Class A Common Share | Disposition | 2024-02-27 | 10,156 | $21.03 | 44,892 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Shares | Share Option | Disposition | 2024-02-27 | 10,156 | $0.00 | 10,156 | $1.86 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
101,061 | 2026-09-13 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.